We are live on ! Find out more
ECYT

Endocyte, Inc. Common Stock
ECYT

Delisted

ECYT was delisted on the 20th of December, 2018.

Back to rankings

111 hedge funds and large institutions have $216M invested in Endocyte, Inc. Common Stock in 2013 Q2 according to their latest regulatory filings, with 111 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.

New
Increased
Maintained
Reduced
Closed

89% more call options, than puts

Call options by funds: $1.55M | Put options by funds: $822K

Holders
111
Holders Change
+111
Holders Change %
–
% of All Funds
3.62%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
111
Increased
–
Reduced
–
Closed
–
Calls
$1.55M
Puts
$822K
Net Calls
+$732K
Net Calls Change
+$732K

Top Buyers

No buyers this quarter

Top Sellers

No sellers this quarter
Name Holding Trade Value Shares
Change 		Change in
Stake
LCG
51
Lisanti Capital Growth
New York
$667K +$500K +37,100 New
State Board of Administration of Florida Retirement System
52
State Board of Administration of Florida Retirement System
Florida
$651K +$668K +49,568 New
TFCP
53
Twin Focus Capital Partners
Massachusetts
$605K +$622K +46,110 New
RIM
54
Rainier Investment Management
Washington
$590K +$606K +44,910 New
DL
55
Delta Lloyd
Netherlands
$541K +$555K +41,166 New
Royal Bank of Canada
56
Royal Bank of Canada
Ontario, Canada
$539K +$554K +41,072 New
ERSOT
57
Employees Retirement System of Texas
Texas
$538K +$553K +41,000 New
Nomura Holdings
58
Nomura Holdings
Japan
$528K +$542K +40,171 New
TA
59
Teachers Advisors
New York
$522K +$536K +39,788 New
UOC
60
UBS O'Connor
Illinois
$499K +$512K +38,000 New
ARTA
61
A.R.T. Advisors
New York
$478K +$492K +36,470 New
BP
62
Ballentine Partners
Massachusetts
$469K +$482K +35,732 New
Acadian Asset Management
63
Acadian Asset Management
Massachusetts
$462K +$475K +35,208 New
JP Morgan Chase
64
JP Morgan Chase
New York
$442K +$454K +33,645 New
RhumbLine Advisers
65
RhumbLine Advisers
Massachusetts
$382K +$393K +29,131 New
DM
66
Deerfield Management
New York
$364K +$374K +27,708 New
SCM
67
Stonebridge Capital Management
California
$352K +$361K +26,785 New
Renaissance Technologies
68
Renaissance Technologies
New York
$348K +$357K +26,500 New
NPF
69
Norris Perne & French
Michigan
$348K +$358K +26,550 New
MLICM
70
Metropolitan Life Insurance Company (MetLife)
New York
$344K +$353K +26,208 New
ProShare Advisors
71
ProShare Advisors
Maryland
$343K +$352K +26,126 New
Manulife (Manufacturers Life Insurance)
72
Manulife (Manufacturers Life Insurance)
Ontario, Canada
$335K +$344K +25,489 New
JWM
73
Jacobus Wealth Management
Wisconsin
$328K +$337K +25,000 New
U
74
UBS
Switzerland
$324K +$332K +24,627 New
Swiss National Bank
75
Swiss National Bank
Switzerland
$307K +$316K +23,400 New
1 2
3
4 5

ECYT Hedge Fund Activity: Q2 2013 in Review

111 of the 3,065 institutional investors tracked by Wall St. Rank reported a position in Endocyte, Inc. Common Stock (ECYT) for Q2 2013, worth a combined $216M.

Buyers outnumbered sellers: 111 funds opened new ECYT positions and 0 closed out — a net gain of 111 holders — while 0 added to existing stakes and 0 trimmed.

  • 111 institutional investors held Endocyte, Inc. Common Stock (ECYT) as of Q2 2013, up from 0 in Q1 2013.
  • Funds reported $216M of Endocyte, Inc. Common Stock stock for Q2 2013.
  • 111 funds opened new Endocyte, Inc. Common Stock positions in Q2 2013 and 0 closed out, a net change of +111 holders.

Based on aggregated 13F filings for Q2 2013.